Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single Center, Open Label, Phase 1 Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Subjects With Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)

Next Previous
X
Search
Trial Profile

Single Center, Open Label, Phase 1 Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Subjects With Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Troculeucel (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment
  • Focus Adverse reactions
  • Acronyms ASK-AD
  • Sponsors NKGen Biotech

    • Most Recent Events

    • 08 Oct 2024 According to a NKGen Biotech media release, abstracts accepted as poster presentations will also be included in the special CTAD edition of the Journal of Prevention of Alzheimer's Disease (JPAD), the official journal of the CTAD conference.
    • 08 Oct 2024 According to a NKGen Biotech media release, interim phase 1 results will be presented at the 17th Annual Clinical Trials on Alzheimer's Disease Conference to be held in Madrid, Spain from October 29-November 1, 2024.
    • 18 Apr 2024 According to a NKGen Biotech media release, data from this trial will be presented at the 12th Annual Alzheimers & Parkinsons Drug Development Summit

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top